Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder

Behaviour Research and Therapy

Volumn 51, Issue 12, 2013, Pages 823-829

  Storch, Eric A ^a   Bussing, Regina ^b   Small, Brent J ^a   Geffken, Gary R ^b   McNamara, Joseph P ^b   Rahman, Omar ^a   Lewin, Adam B ^a   Garvan, Cynthia S ^b   Goodman, Wayne K ^c   Murphy, Tanya K ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Mt Sinai Liver Cancer Program   (United States)

Author keywords

Children; Cognitive behavioral therapy; Obsessive compulsive disorder; Sertraline; Treatment

Indexed keywords

PLACEBO; SERTRALINE;

ADOLESCENT; APPETITE; ARTICLE; BEHAVIOR DISORDER; CHILD; CHILD OBSESSIVE COMPULSIVE IMPACT SCALE-PARENT AND CHILD; CHILDREN DEPRESSION RATING SCALE-REVISED; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; COMMON COLD; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; MALE; MULTICENTER STUDY; MULTIDIMENSIONAL ANXIETY SCALE FOR CHILDREN; MYALGIA; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SORE THROAT; STOMACH PAIN; SUICIDAL IDEATION; TIC; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

CHILDREN; COGNITIVE-BEHAVIORAL THERAPY; OBSESSIVE-COMPULSIVE DISORDER; SERTRALINE; TREATMENT;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PATIENT COMPLIANCE; SERTRALINE; TREATMENT OUTCOME;

EID: 84886428782     PISSN: 00057967     EISSN: 1873622X     Source Type: Journal    
DOI: 10.1016/j.brat.2013.09.007     Document Type: Article

References (26)

1. AACAP Practice parameters for the assessment and treatment of pediatric obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2012, 51:98-113.
2. van Balkom A.J., de Haan E., van Oppen P., Spinhoven P., Hoogduin K.A., van Dyck R. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. Journal of Nervous and Mental Disease 1998, 186(8):492-499.
3. Cottraux J., Mollard E., Bouvard M., Marks I., Sluys M., Nury A.M., et al. Acontrolled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology 1990, 5(1):17-30.
4. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry 2005, 162:151-161.
5. Franklin M.E., Sapyta J., Freeman J.B., Khanna M., Compton S., Almirall D., et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA 2011, 306(11):1224-1232.
6. Geller D.A., Biederman J., Stewart S.E., Mullin B., Farrell C., Wagner K.D., et al. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?. Journal of Child and Adolescent Psychopharmacology 2003, 13(Suppl.1):S19-S29.
7. Hamer R.M., Simpson P.M. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. American Journal of Psychiatry 2009, 166:639-641.
8. Hohagen F., Winkelmann G., Rasche-Ruchle H., Hand I., Konig A., Munchau N., et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. British Journal of Psychiatry 1998, (Suppl.35):71-78.
9. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P., et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36(7):980-988.
10. Littell R.C., Milliken G.A., Stroup W.W., Wolfinger R.D., Schabenberger O. SAS for mixed models 2006, SAS Press, Cary, NC. 2nd ed.
11. March J.S., Parker J.D., Sullivan K., Stallings P., Conners C.K. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36(4):554-565.
12. Marks I.M., Lelliott P., Basoglu M., Noshirvani H., Monteiro W., Cohen D., et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. British Journal of Psychiatry 1988, 152:522-534.
13. Marks I.M., Stern R.S., Mawson D., Cobb J., McDonald R. Clomipramine and exposure for obsessive-compulsive rituals: i. British Journal of Psychiatry 1980, 136:1-25.
14. Marques L., LeBlanc N.J., Weingarden H.M., Timpano K.R., Jenike M., Wilhelm S. Barriers to treatment and service utilization in an internet sample of individuals with obsessive-compulsive symptoms. Depression and Anxiety 2010, 27:470-475.
15. Murphy T.K., Segarra A., Storch E.A., Goodman W.K. SSRI adverse events: how to monitor and manage. International Review of Psychiatry 2008, 20(2):203-208.
16. National Institute of Mental, H CGI (Clinical Global Impression) Scale - NIMH. Psychopharmacology Bulletin 1985, 21:839-844.
17. Pauls D.L., Alsobrook J.P., Goodman W., Rasmussen S., Leckman J.F. Afamily study of obsessive-compulsive disorder. American Journal of Psychiatry 1995, 152:76-84.
18. Piacentini J., Bergman R.L., Keller M., McCracken J. Functional impairment in children and adolescents with obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology 2003, 13(Suppl.1):S61-S69.
19. POTS Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004, 292(16):1969-1976.
20. Poznanski E.O., Mokros H.B. Children's Depression Rating Scale-Revised 1996, Western Psychological Services, Los Angeles.
21. Scahill L., Riddle M.A., McSwiggin-Hardin M., Ort S.I., King R.A., Goodman W.K., et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36(6):844-852.
22. Singer J.D., Willett J.B. Applied longitudinal data analysis: Modeling change and event occurrence 2003, Oxford University Press, New York, NY.
23. Storch E.A., Lewin A.B., De Nadai A.S., Murphy T.K. Defining treatment response and remission in obsessive-compulsive disorder: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale. Journal of the American Academy of Child and Adolescent Psychiatry 2010, 49(7):708-717.
24. Storch E.A., Murphy T.K., Geffken G.R., Soto O., Sajid M., Allen P., et al. Psychometric evaluation of the Children's Yale-Brown Obsessive-Compulsive Scale. Psychiatry Research 2004, 129(1):91-98.
25. Tenneij N.H., van Megen H.J., Denys D.A., Westenberg H.G. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. Journal of Clinical Psychiatry 2005, 66(9):1169-1175.
26. Walsh K.H., McDougle C.J. Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Expert Opinions in Pharmacotherapy 2004, 5(10):2059-2067.